Cardiovascular-Related Mortality Risk in Primary Myelofibrosis in Pre-Ruxolitinib and Ruxolitinib Eras

被引：0
作者：
Ilerhunmwuwa, Nosakhare Paul [1 ]
Rayapureddy, Aditya Keerthi [2 ]
Uche, Ifeanyi Nnamdi [1 ]
Wasifuddin, Mustafa [3 ]
Wang, Jen-Chin [4 ]
机构：
[1] Brookdale Univ Hosp & Med Ctr, Dept Med, Brooklyn, NY USA
[2] Interfaith Med Ctr, Dept Med, Brooklyn, NY USA
[3] Brookdale Univ Hosp & Med Ctr, Brooklyn, NY USA
[4] Brookdale Univ Hosp & Med Ctr, Div Hematol Oncol, Brooklyn, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174418
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
[31]   Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib [J].
Rajasekaran, Arun ;
Thuy-Trang Ngo ;
Abdelrahim, Maen ;
Glass, William ;
Podoll, Amber ;
Verstovsek, Srdan ;
Abudayyeh, Ala .
BMC NEPHROLOGY, 2015, 16
[32]   The Journey of Primary Myelofibrosis to Splenic Marginal Zone Lymphoma on the Wheels of Ruxolitinib [J].
Jasmita Dass ;
Sabina Langer ;
Jyoti Kotwal ;
Nitin Gupta .
Indian Journal of Hematology and Blood Transfusion, 2021, 37 :186-188
[33]   Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib [J].
Branco, Benoit ;
Metsu, David ;
Dutertre, Marine ;
Marchou, Bruno ;
Delobel, Pierre ;
Recher, Christian ;
Martin-Blondel, Guillaume .
ANNALS OF HEMATOLOGY, 2016, 95 (07) :1207-1209
[34]   Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib [J].
Arun Rajasekaran ;
Thuy-Trang Ngo ;
Maen Abdelrahim ;
William Glass ;
Amber Podoll ;
Srdan Verstovsek ;
Ala Abudayyeh .
BMC Nephrology, 16
[35]   Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib [J].
Kumar, Sandhya Shanthosh ;
Nagesh, Vignesh Krishnan ;
Sivakolundu, Keerthana P. ;
Ali, Bahadur ;
Sange, Ibrahim .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
[36]   Local experience with ruxolitinib in primary and secondary myelofibrosis: an analysis of 10 patients treated with ruxolitinib in the Hull and East Yorkshire NHS Trust [J].
Owen, M. L. ;
Ali, S. ;
Green, S. ;
Fletcher, A. .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 :77-78
[37]   Real-life ruxolitinib experience in intermediate-risk myelofibrosis [J].
Arikan, Fatma ;
Toptas, Tayfur ;
Atagunduz, Isik Kaygusuz ;
Ercan, Tarik ;
Oruc, Ozen ;
Yilmaz, Fergun ;
Tuglular, Tulin .
BLOOD RESEARCH, 2021, 56 (04) :322-331
[38]   Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia [J].
Pope, Victor ;
Hsia, Cyrus C. .
ANNALS OF HEMATOLOGY, 2024, 103 (02) :677-679
[39]   Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib [J].
Zhou, Amy ;
Kong, Tim ;
Fowles, Jared S. ;
Jung, Chun-Ling ;
Allen, Maggie J. ;
Fisher, Daniel A. C. ;
Fulbright, Mary ;
Nemeth, Elizabeta ;
Ganz, Tomas ;
Oh, Stephen T. .
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (04) :E49-E52
[40]   Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia [J].
Victor Pope ;
Cyrus C. Hsia .
Annals of Hematology, 2024, 103 :677-679
12345